Epsikapron en es it fr

Epsikapron Brand names, Epsikapron Analogs

Epsikapron Brand Names Mixture

  • No information avaliable

Epsikapron Chemical_Formula


Epsikapron RX_link


Epsikapron fda sheet

Epsikapron FDA

Epsikapron msds (material safety sheet)

Epsikapron MSDS

Epsikapron Synthesis Reference

No information avaliable

Epsikapron Molecular Weight

131.173 g/mol

Epsikapron Melting Point

205 oC

Epsikapron H2O Solubility

5.05E+005 mg/L

Epsikapron State


Epsikapron LogP


Epsikapron Dosage Forms

Solution for injection (containing 250 mg/mL of aminocaproic acid) and tablets (500, 1000mg)

Epsikapron Indication

For use in the treatment of excessive postoperative bleeding.

Epsikapron Pharmacology

Aminocaproic acid works as an antifibrinolytic. It is a derivative of the amino acid lysine. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity.

Epsikapron Absorption

Absorbed rapidly following oral administration. In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1).

Epsikapron side effects and Toxicity

A few cases of acute overdosage with intravenous administration have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. The intravenous and oral LD50 were 3.0 and 12.0 g/kg respectively in the mouse and 3.2 and 16.4 g/kg respectively in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog.

Epsikapron Patient Information

Epsikapron Organisms Affected

Humans and other mammals